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October 2013 preadmission dependency, and dementia constitute a challenge when deciding about thrombolysis treatment. Patients and families wonder about the likelihood of a clinically meaningful recovery if tPA is given, especially in situations where in which the risk of a poor outcome or hemorrhagic complications is high. As a result, the prediction of response to intravenous thrombolysis may be useful for patients, their families, and clinicians in discussions related to the decision to give intravenous thrombolysis. A previous study from our group showed that the iScore predicts favorable outcome at discharge in >12 000 stroke patients from Canada. 8, 9 An iScore ≥200 was associated with no significant improvement after tPA and higher risk of intracerebral hemorrhages compared with propensity-matched controls. 10, 11 Our objective was to evaluate the ability of the iScore to predict clinical outcomes at 3 months in acute ischemic stroke patients treated with or without tPA in the Virtual International Stroke Trials Archive (VISTA).
Methods
We applied the iScore to participants with ischemic stroke in the VISTA database. VISTA (www.vista.gla.ac.uk/) is a collaborative registry that includes data from completed acute stroke/neuroprotective clinical trials and provides access to anonymized data for exploratory analyses. Further details of VISTA were published elsewhere. 12, 13 It is important to note that this database does not include trials of tPA therapy, per se, although tPA was commonly used as an adjunctive therapy.
For the purpose of this analysis, relevant data were extracted from the VISTA database that met the following entry criteria: (1) minimum dataset of 100 patients; (2) documented entry criteria; (3) baseline assessment within 24 hours of stroke onset, including recording of neurological deficit by National Institutes of Health Stroke Scale (NIHSS); (4) confirmation of stroke diagnosis by cerebral imaging within 7 days; and (5) outcome assessed 3 months after stroke onset. This analysis is based on a total of 7140 patients participating in 4 neuroprotective trials who met the aforementioned inclusion criteria. Onset-to-treatment represents the elapsed time from stroke onset to receiving the studied intervention treatment (not tPA).
The iScore comprises 10 variables that were included in VISTA (Table I in the online-only Data Supplement). Details of the selection of variables for the iScore, data sources, and the creation and conceptualization of the iScore have been published elsewhere. 8, 9 Stroke subtype was categorized as lacunar versus nonlacunar. Similar to previous studies, renal failure was defined as a baseline creatinine ≥400 mg/L. 8, 9 
Outcome Measures
The primary outcome was favorable outcome, defined as modified Rankin scale score (mRS) of 0 to 2 at 3 months. We also analyzed a composite favorable outcome defined as an mRS of 0 to 1 or an NIHSS ≤1 at 3 months. Secondary 3-month outcomes included catastrophic outcome (defined as an mRS of 4-6), death, Barthel index (BI) >90, and NIHSS 0 to 1.
Statistical Analysis
We compared the characteristics between patients with an iScore <200 and those with an iScore ≥200 using χ 2 test for categorical variables and t test was used to compare mean differences for continuous variables. Mantel-Haenszel test was used in the analysis of stratified categorical data. The primary analysis was conducted to evaluate the association between tPA therapy and 3-month outcomes of interest according to different iScore strata. Because previous studies showed that an iScore ≥200 was associated with poor outcomes, 11 we used the same binary cut-off point and tested other cut points in a sensitivity analysis. The independent associations between tPA therapy and outcomes were determined using multivariable logistic regression.
Adjustments for age, baseline NIHSS, iScore (<200 versus ≥200), and onset-to-treatment time for the non-tPA intervention agent were made because of differences in baseline characteristics between patients receiving and not receiving tPA (Table II in the online-only Data Supplement). To determine whether a differential effect of tPA on outcomes was present according to different levels of the iScore (<200 versus ≥200), we tested the significance of the iScore*tPA interaction term in the multivariable models. We conducted a sensitivity analysis to compare different cut-off points of the iScore (eg, 180, 200, and 220) expressed as the area under the curve. We also conducted a sensitivity analysis by excluding patients with an NIHSS ≥25.
Statistical analysis was performed using STATA version 9 (StataCorp LP; College Station, TX). Rocgold command was used to compare area under the curves for different iScore cut-off points. All tests were 2-tailed, and P values <0.05 were considered significant.
Results
Among 7140 patients with an acute ischemic stroke, 2732 (38.5%) received tPA, and 711 (10%) had an iScore ≥200. 
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Further details by the iScore strata are summarized in Table II in the online-only Data Supplement.
Primary Outcome Measures
Among participants with an iScore <200, favorable outcome at 3 months (mRS ≤2) was observed in 47.5% of tPA patients and 38.9% in the non-tPA (untreated) group (P<0.001; Figure 1 ). For patients with an iScore ≥200, favorable outcomes occurred only in the minority of patients, and there was no difference between tPA and non-tPA groups (7.6% versus 5.4%; P=0.45; Figure 1 ).
Multivariable-adjusted analyses of the primary outcome are represented in Table 2 . Because the analysis demonstrated a significant interaction effect (P<0.001) between tPA and the iScore on the primary outcome, we present all analyses separately for patients with an iScore <200 versus ≥200.
In the multivariable analysis after adjusting for age, baseline NIHSS, and onset-to-intervention treatment, tPA administration was associated with a 47% higher chance of a favorable outcome at 3 months among patients with an iScore <200 (odds ratio [OR], 1.47; 95% confidence interval [CI], 1.30-1.67). Contrarily, no significant benefit of tPA treatment was observed for those with an iScore ≥200 (OR, 0.80; 95% CI, 0.45-1.42; Table 2 ). Similar findings were observed for a composite favorable outcome.
Secondary Functional Outcomes
Statistically significant interaction effects between the iScore and tPA were demonstrated for death at 3 months (P<0.001) and catastrophic outcome (death or disability) at 3 months (P<0.001). There was no significant interaction for either the BI (P=0.47) or the NIHSS (P=0.70) outcomes.
Among patients with an iScore <200, there was a significant improvement at 3 months for all secondary outcomes with tPA treatment. Contrarily, no significant improvement in outcomes after tPA therapy was detected among patients with an iScore ≥200, with the exception of catastrophic outcomes (Table 2 and Figure 2 ).
tPA administration in stroke patients with an iScore ≥200 was associated with a 46% lower odds of catastrophic outcome (death or disability) at 3 months (OR, 0.54; 95% CI, 0.35-0.83).
Sensitivity Analysis
The sensitivity analysis showed no change in the performance of other cut-off points (eg, iScore 180 or 220) for all the studied outcomes (Table III in the online-only Data Supplement). There was no significant difference between the areas under the curve that would justify a different cut-off point.
Because in some institutions, stroke patients with an NIHSS ≥25 may not receive tPA, a post hoc analysis was conducted excluding these cases. There was no difference in the proportion of patients with an NIHSS ≥25 between tPA and nontPA patients (2.6% versus 2.5%; P=0.84). Moreover, there was no difference in an NIHSS ≥25 between tPA and nontPA patients among those with an iScore ≥200 (22.8% versus 24.2%; P=0.65). After patients with an NIHSS ≥25 were excluded, there remained no significant association between [15] [16] [17] Clinicians need practical and validated tools when discussing prognosis with stroke patients and their families.
In this study, we applied the iScore and analyzed a variety of clinical outcomes after thrombolysis in the VISTA data set. Overall, patients with an iScore ≥200 had a 9-fold higher risk of death and disability at 3 months and a lower chance of a favorable outcome. Furthermore, tPA administration was consistently associated with better outcomes (mRS, 0-2, death, Barthel index, >90, NIHSS 0-1 at 3 months) among stroke patients with an iScore <200, but no benefit was observed for those with an iScore ≥200 when compared with the non-tPA group. The benefit of tPA in decreasing catastrophic outcomes for patients with an iScore ≥200 was likely explained by a ceiling effect because a substantially higher number of patients achieved a bad outcome (86.2% non-tPA versus 75.2% tPA), and thus, increasing the probability of detecting significant differences. The lack of better outcomes with tPA among patients with an iScore ≥200 was irrespective of the baseline NIHSS. Finally, we found an interaction between tPA and the iScore, suggesting the iScore may predict clinical outcomes after tPA.
In a recent study, our group found that patients with an iScore >200 had no apparent benefit from intravenous tPA and a 3-fold higher risk of hemorrhagic complications (20% versus 6%; P<0.001). 11 We also found an interaction between tPA and the iScore for favorable outcome at discharge. When the iScore was applied to the National Institute of Neurological Disorders and Stroke Tissue-Type Plasminogen Activator Stroke trial, an iScore >200 was associated with higher risk of ICH (30.8% tPA versus 11.5% placebo; P=0.014) and no significant benefit for tPA (for an mRS 0-2 at 3 months: 18.5 tPA versus 11.5 placebo, OR, 1.73; 95% CI, 0.60-4.99). In this study, participants having an iScore >200 had an even lower probability of a favorable outcome at 3 months, with no significant difference between patients receiving (9.9%) and not receiving (8.9%) tPA (OR, 0.80; 95% CI, 0.45-1.42). In addition, our study confirms that other cut-off points do not improve the performance of the iScore. More important, our results are consistent with previous findings and reveal that the prognostic value of the iScore for functional clinical outcomes is extended to 90 days.
Our study has some limitations that deserve comment. First, we cannot rule out a selection bias for tPA treatment considering the nonrandomized data even when derived from clinical trials.
12,13 Second, we cannot rule out the possibility of Values in parentheses are column raw percentages, unless otherwise indicated. Composite favorable outcome defined as a mRS of 0 or 1 and NIHSS≤1 at 3 months. Catastrophic functional outcome defined as a mRS of 4 to 6 at 3 months. mRS for the estimations of favorable outcome and catastrophic outcome were available for 6768 patients. CI indicates confidence interval; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; and rtPA, recombinant tissue-type plasminogen activator.
*Represents the OR (95% CI) for rtPA in the logistic regression analysis adjusted for age, baseline NIHSS, and onset-to-treatment. † Statistically significant results. http://stroke.ahajournals.org/ a type II error related to smaller sample sizes for patients with an iScore ≥200 or residual confounding even after completing a multivariable analysis. This study may be useful to facilitate discussions about thrombolysis with stroke patients and their families. Previous studies showed clinicians are not accurate in predicting the risk of intracerebral hemorrhage or response to tPA. 18 In a randomized study comparing clinician estimations (n=1661) and the iScore with actual stroke outcomes, only 17% of clinicians caring for stroke patients were able to accurately estimate actual death or disability compared with 80% to 90% accurate predictions by the iScore. These findings revealed the importance of using validated risk tools compared with single physician clinical experience. 19 We showed that stroke patients with an iScore ≥200 had a 9-fold risk of death or disability at 3 months with no significant improvement with tPA. After adjustment, only 5% to 6% of those patients were independent at 3 months (Figure 1 ). Despite the limited effectiveness of tPA in patients with a high iScore, some clinicians and families may still want to proceed with intravenous tPA in the absence of contraindications or when other therapeutic alternatives are not available.
In summary, the iScore is a simple, validated risk score, applicable to most common acute clinical settings that can be used by emergency physicians, internists, and neurologists when counseling patients and families. The iScore differentially identifies the likelihood of a favorable outcome at 3 months after tPA.
Univariate analysis for different outcome measures using the iScore as a continuous and categorical variable:
A higher iScore (continuous) was associated with a lower risk of a favorable 0utcome (mRS 0-2) at 3 months (OR 0.977; 95%CI 0.975-0.978; p<0.001). Similar trend was observed for an iScore ≥200 (categorical) compared to an iScore <200 (OR 0.120; 95%CI 0.092-0.157; p<0.001).
A higher iScore was associated with an increased risk of death and disability (OR 1.027; 95%CI 1.025-1.029), death (OR 1.024; 95%CI 1.022-1.026) and a lower probability of achieving a BI >90 (OR 0.977; A higher iScore (continuous) was associated with higher risk of death and disability (OR 1.027; 95%CI
1.025-1.029), death (OR 1.024; 95%CI 1.022-1.026) and a lower probability of achieving a BI >90 (OR 0.977; 95%CI 0.976-0.979) at 3 months after tPA.
In the univariate analysis, an iScore ≥200 (categorical) was associated with nine fold higher risk of death and disability at 3 months (OR 9.41, 95%CI 7.00-12.6) and fivefold higher risk of death at 3 months (OR 5.18; 95%CI 4.37-6.15) compared to patients with iScore <200. Values represent the area under the curve (AUC) estimated from logistic regression analyses for the outcomes of interest adjusted by tPA, OTT, age and NIHSS for each iScore cutoff.
There was no significant difference when compare the established iScore cutoff of 200 with other cutoff points for any of the analyzed outcomes. Definition of favorable and catastrophic outcomes as described in Table 2 in the text. 
